MarginsXMarginsX
Home › Markets › Health Care › WHWK

Whitehawk Therapeutics Inc. (WHWK)

WHWK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.01
-1.63% on the day
Market cap
$177.6M
Micro cap
Revenue · 2025
$7.1M
-72.5% on 2024
Net income · 2025
-$20.6M
-288.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/0001193125-26-104158-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerWHWK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001422142
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$7.1M
Net income-$20.6M
Operating income-$114.4M
Net margin-288.3%
Operating margin-1601.1%
Revenue growth-72.5%
Cash$37.6M
Total assets$150.8M
P/E (computed)Net income was not positive
P/S (computed)24.9×

Warning signs

Cash runway
11.2 months
$69.0M cash at September 30, 2026
Share count, 1 year
+25.2%
2025-11-04 to 2026-11-05 · +140.6% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$2.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$69.0M cash; operating cash flow -$18.4M a quarter.Report 2026-09-30
Shares outstanding59,008,982 (2026-11-05); 47,128,362 a year earlier; 24,525,860 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., San Diego, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$21.2M-$19.7M$69.0MNo debt tags$010-Q 2026-11-09
Q2 2026
2026-06-30
$0-$16.6M-$14.5M$85.2MNo debt tags$010-Q 2026-08-06
Q1 2026
2026-03-31
$0-$22.2M-$22.2M$34.8MNo debt tags$010-Q 2026-05-07
Q4 2025
2025-12-31
$0-$23.3M-$17.2M$37.6MNo debt tags$7.1M10-K 2026-03-12
Q3 2025
2025-09-30
$0-$17.7M-$15.4M$37.9MNo debt tags$14.4M10-Q 2026-11-09
Q2 2025
2025-06-30
$0-$52.6M-$53.0M$144.9MNo debt tags$21.6M10-Q 2026-08-06
Q1 2025
2025-03-31
$7.1M$73.0M-$11.9M$227.6MNo debt tags$27.8M10-Q 2026-05-07
Q4 2024
2024-12-31
$7.2M-$18.3M-$15.1M$28.7MNo debt tags$26.0M10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-05-29
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 676 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.2%
1 month+1.3%
3 months-34.6%
Year to date+26.4%
1 year+46.4%
From 52-week high-40.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SLGLSol-Gel Technologies Ltd.$54.96-0.29%$179.9M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
NATRNature's Sunshine Products Inc.$10.56+1.93%$183.0M
RNACCartesian Therapeutics Inc.$6.08-4.25%$185.5M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier